Pfizer's COVID-19 vaccine over 90 percent effective in interim analysis
A coronavirus vaccine candidate in development from Pfizer and BioNTech was found to be more than 90 percent effective against COVID-19 in a first interim analysis, the companies announced on Monday.
Pfizer said that an early analysis of 94 participants suggests "a vaccine efficacy rate above 90 percent." This was a better rate than anticipated, and the FDA has said it would authorize a vaccine that's at least 50 percent effective, The Wall Street Journal notes. Dr. Anthony Fauci, the nation's top infectious disease expert, has also said he would "settle" for a vaccine that's between 70 and 75 percent effective.
"Today is a great day for science and humanity," Pfizer CEO Albert Bourla said. "With today's news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The news comes as the United States passes 10 million confirmed cases of COVID-19. Kathrin Jansen, Pfizer's head of vaccine research and development, told The Washington Post this is a "historical moment," adding that "hearing that at the interim analysis we are over 90 percent effective — it was almost stunning to hear." Still, The New York Times notes that this announcement is "not conclusive evidence that the vaccine is safe and effective, and the initial finding of more than 90 percent efficacy could change as the trial goes on."
Pfizer had previously said it could seek emergency use authorization from the Food and Drug Administration for its vaccine candidate in the third week of November, and Bourla on Monday said that "we look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Dresden: on the trail of a Romantic icon in Germany
the week recommends The Saxon city celebrates the 250th birthday of Caspar David Friedrich this year
By The Week UK Published
-
5 tremendously trending cartoons on the TikTok showdown
Cartoons Artists take on Chinese influence, privacy concerns, and more
By The Week US Published
-
Recipe: nasi goreng spicy fried rice
The Week Recommends Perfect for weeknights, this gluten-free twist on Indonesian fried rice is 'oh-so-good'
By The Week UK Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Sunak on 'wrong side of history' as MPs vote on infected blood payments
Speed Read PM suffers first Commons defeat after Tory rebels back move to speed up compensation for victims
By The Week UK Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published